Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q4 FY26 results · Jan–Mar 2026
Lincoln Pharmaceuticals reported revenue from operations of ₹187.28 crore (up 11.4% from Q4 FY25) and net profit of ₹11.63 crore (up 0.5% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 187.28 | 168.18 | +11.4% | 166.32 | +12.6% |
| Other income | (4.20) | (6.88) | Loss narrowed | 15.15 | Turned loss |
| Total income | 183.08 | 161.30 | +13.5% | 181.47 | +0.9% |
| Profit before tax | 16.70 | 16.25 | +2.8% | 34.72 | −51.9% |
| Net profit for the period | 11.63 | 11.57 | +0.5% | 28.60 | −59.3% |
| EPS, basic (₹) | 5.81 | 5.78 | +0.5% | 14.28 | −59.3% |
| Net margin (%) | 6.2 | 6.9 | 17.2 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 187.28 | 168.18 | +11.4% | 166.32 | +12.6% |
| Other income | (4.20) | (6.88) | Loss narrowed | 15.15 | Turned loss |
| Total income | 183.08 | 161.30 | +13.5% | 181.47 | +0.9% |
| Profit before tax | 16.70 | 16.25 | +2.8% | 34.72 | −51.9% |
| Net profit for the period | 11.63 | 11.57 | +0.5% | 28.60 | −59.3% |
| EPS, basic (₹) | 5.81 | 5.78 | +0.5% | 14.28 | −59.3% |
| Net margin (%) | 6.2 | 6.9 | 17.2 |
Consolidated
- Filed with BSE
- 28 May 2026, 20:51 IST
- Board meeting
- 28 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 May 2026, 20:51 IST
- Board meeting
- 28 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE